For more information call (888) LUHS-888.
Patients must have unresectable advanced or metastatic histologically or cytologically confirmed adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJ); patients must not have received treatment for metastatic or unresectable disease or have brain metastases; patients must have measurable and/or non-measurable disease. CT scans or MRIs used to assess measurable disease must have been completed within 28 days prior to registration. CT scans or MRIs used to assess non-measurable, disease must have been completed within 42 days prior to registration. All disease must be assessed and documented on the Baseline Tumor Assessment Form (RECIST 1.1); patients who have had HER-2 expression testing prior to registration to this study must be HER-2 negative, and if HER-2 expression has not been tested prior to registration to this study, tissue specimen must be submitted for HER-2 expression; patients must have a Zubrod performance status of 0-1; patients must have adequate hematologic, hepatic and kidney functions; women and men of reproductive potential must have agreed to use an effective contraceptive method; patients must have completed any prior neoadjuvant and adjuvant therapy for resectable disease at least 180 days prior to registration.
The purpose of this study is to find out what effects (good and bad) a targeted therapy approach (specific treatment that is based on certain genes found in tumor cells) has on you and your esophageal, gastric, or gastroesophageal junction cancer.